Avery Dennison Q2 Earnings Beat Estimates, Revenues Dip Y/Y

Avery Dennison (AVY) reported Q2 2025 adjusted EPS of $2.42, surpassing analyst estimates, but revenues declined 0.7% year-over-year to $2.22 billion, missing expectations primarily due to organic sales decreases in both its Materials and Solutions Groups. Gross profit also fell 3.6% year-over-year, and long-term debt increased to $2.63 billion. Despite returning $503 million to shareholders in the first half, AVY's shares have underperformed, declining 18.7% over the past year, with the company forecasting Q3 adjusted EPS between $2.24 and $2.40.

Analysis

Avery Dennison's second-quarter 2025 results present a challenging operational picture despite an earnings beat. The company reported an adjusted EPS of $2.42, which surpassed the Zacks Consensus Estimate but remained flat year-over-year, indicating that profitability is not expanding. This bottom-line performance was largely driven by cost management, as evidenced by lower SG&A expenses and $30 million in restructuring savings, which helped maintain a flat adjusted operating margin of 12.9%. However, this masks fundamental top-line weakness, with revenues declining 0.7% to $2.22 billion and missing estimates. Critically, organic sales contracted in both the Materials Group (-1.0%) and the Solutions Group (-0.8%), directly contradicting analyst models that had predicted growth. The balance sheet also shows signs of strain, with long-term debt increasing by nearly $600 million year-over-year to $2.63 billion, while the company returned $503 million to shareholders in the first half. The Q3 EPS guidance, with a midpoint of $2.32, suggests a potential sequential earnings decline. This performance, coupled with the stock's 18.7% drop over the past year, places it in stark contrast to industry peers who are forecast to deliver robust top and bottom-line growth.

Key Decisions for Investors

• Investors should treat the EPS beat with caution, as it is overshadowed by negative organic growth across both business segments and a year-over-year revenue decline.
• The significant increase in long-term debt to $2.63 billion, concurrent with a substantial $503 million capital return program, warrants close scrutiny of the company's capital allocation strategy and balance sheet health.
• Considering the stock's significant underperformance relative to its industry and a lackluster Q3 earnings guidance, it is prudent to monitor for a turnaround in top-line trends before taking a more constructive view, especially when peers are exhibiting stronger growth outlooks.